PHILADELPHIA, June 2, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today reported that it has completed enrollment in a Phase II clinical trial to evaluate the safety and efficacy of Ampligen(r) as an enhancer for seasonal influenza vaccine.
